Tempest Therapeutics’ triple combo shows promise in first-line liver cancer, stock jumps
Tempest Therapeutics said Friday morning that its experimental liver cancer therapy on top of standard-of-care treatments helped shrink tumors in more patients compared to standard-of-care alone.
In an early cut of data from a Phase I/II trial, 7 of 40 patients (17.5%) with hepatocellular carcinoma who were treated with Tempest’s TPST-1120 on top of Tecentriq and Avastin as a first option had confirmed responses compared with 3 of 29 (10.3%) who received only Tecentriq and Avastin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.